Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025

Inhibikase Therapeutics, Inc.

2025-Q1 EPS reported -$0.15

Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.
R&D expenses $10.5M (incl. $7.4M IPR&D charge); SG&A $5.2M; cash $93.2M at March 31, 2025.
Appointed new CEO (Mark Iwicki), President/Head of R&D (Chris Cabell), CSO (John Adams), CFO (David McIntyre).
IKT-001 Phase 2b PAH study design finalizing; trial initiation expected H2 2025; FDA 'Study May Proceed' received Sept 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.